Search research articles
Contact Us
Filters
Showing results (361-370 of 423) with videos related to
Page
of 43
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 7, 2019
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
Lisa M Kopp, Suman Malempati, Mark Krailo, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
May 5, 2025
Early compliance with lung cancer lymph node standard 5.8: An analysis of 2022 and 2023 Commission on Cancer site reviews
Alison S Baskin, Elizabeth C Funk, Amanda B Francescatti, et al.
Pediatric Blood & Cancer
|
May 3, 2018
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Eric S Schafer, Rachel E Rau, Stacey Berg, et al.
JCO Clinical Cancer Informatics
|
April 10, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups
Tamara P Miller, Richard Aplenc, Charles Minard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2025
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial
Adam L Green, Charles G Minard, Xiaowei Liu, et al.
JAMA Surgery
|
April 21, 2016
Key Tenets of Effective Surgery Leadership: Perspectives From the Society of Surgical Chairs Mentorship Sessions
Todd K Rosengart, K Craig Kent, Kirby I Bland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
Brenda J Weigel, Susan M Blaney, Joel M Reid, et al.
The Lancet. Oncology
|
April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé, Megan S Lim, Stephan D Voss, et al.
Cancer
|
October 24, 2018
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group
Suman Malempati, Brenda J Weigel, Yueh-Yun Chi, et al.
Cancer Discovery
|
June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
Elliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Page
of 43
Search research articles
Search
Showing results (361-370 of 423) with videos related to
Sort By:
Page
of 43
European Journal of Cancer (Oxford, England : 1990)
|
October 7, 2019
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
Lisa M Kopp, Suman Malempati, Mark Krailo, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
May 5, 2025
Early compliance with lung cancer lymph node standard 5.8: An analysis of 2022 and 2023 Commission on Cancer site reviews
Alison S Baskin, Elizabeth C Funk, Amanda B Francescatti, et al.
Pediatric Blood & Cancer
|
May 3, 2018
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Eric S Schafer, Rachel E Rau, Stacey Berg, et al.
JCO Clinical Cancer Informatics
|
April 10, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups
Tamara P Miller, Richard Aplenc, Charles Minard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2025
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial
Adam L Green, Charles G Minard, Xiaowei Liu, et al.
JAMA Surgery
|
April 21, 2016
Key Tenets of Effective Surgery Leadership: Perspectives From the Society of Surgical Chairs Mentorship Sessions
Todd K Rosengart, K Craig Kent, Kirby I Bland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
Brenda J Weigel, Susan M Blaney, Joel M Reid, et al.
The Lancet. Oncology
|
April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé, Megan S Lim, Stephan D Voss, et al.
Cancer
|
October 24, 2018
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group
Suman Malempati, Brenda J Weigel, Yueh-Yun Chi, et al.
Cancer Discovery
|
June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
Elliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Page
of 43